ADAP - Adaptimmune Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
42,428
59,505
37,833
14,198
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
93,783
98,269
87,388
63,789
Selling General and Administrative
43,027
43,601
31,106
23,208
Total Operating Expenses
136,810
141,870
118,494
86,997
Operating Income or Loss
-94,382
-82,365
-80,661
-72,799
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-8,072
-15,501
8,744
1,002
Income Before Tax
-99,095
-95,017
-69,687
-70,687
Income Tax Expense
335
497
451
892
Income from Continuing Operations
-99,430
-95,514
-70,138
-71,579
Net Income
-99,430
-95,514
-70,138
-71,579
Net Income available to common shareholders
-99,430
-95,514
-70,138
-71,579
Reported EPS
Basic
-
-0.96
-0.78
-1.02
Diluted
-
-0.96
-0.78
-1.02
Weighted average shares outstanding
Basic
-
97,390
87,940
70,786
Diluted
-
97,390
87,940
70,786
EBITDA
-
-74,555
-75,238
-69,513